LearnTransfusion Series

Topic Teaching: Laboratory Issues Encountered with New Haemophilia Treatments

10 novembre, 2020 | 12:00 - 13:00 (EDT)


Presented by:

Dr. Muntadhar Al Moosawi, MD
Hematopathology Resident
University of British Columbia


1.    Review the different hemophilia A and B treatment options provided by CBS.
2.    Understand the mechanisms used to modify factor VIII and IX products to extend their half life.
3.    Learn about the different reagents and assays used for the measurement of factor VIII and IX levels.
4.    Learn about the interference of extended half life factor VIII and IX products with factor assays.
5.    Learn about the interference of emicizumab with coagulation assays.


1.    Dunn A. The long and short of it: using the new factor products. Hematology Am Soc Hematol Educ Program. 2015;2015:26-32.
2.    Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jiménez-Yuste, V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy, GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822.
3.    https://blood.ca/sites/default/files/PPP_Customer_Table_of_Information_2020-01-06.pdf
4.    Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia. 2015 Jul;21(4):550-7.
5.    Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015 Feb;94 Suppl 77:38-44.
6.    Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016 Feb;14(2):248-61.
7.    Church N, Leong L, Katterle Y, Ulbrich HF, Noerenberg I, Kitchen S, Michaels LA. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study. Haemophilia. 2018 Sep;24(5):823-832.
8.    Pruthi RK. Laboratory monitoring of new hemostatic agents for hemophilia. Semin Hematol. 2016 Jan;53(1):28-34. doi: 10.1053/j.seminhematol.2015.10.003.
9.    Turecek PL, Romeder-Finger S, Apostol C, Bauer A, Crocker-Buqué A, Burger DA, Schall R, Gritsch H. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.  Haemophilia. 2016 Nov;22(6):957-965.
10.   Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia:  Impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost.  2020 Jun;18(6):1242-1255.
11.    Adamkewicz JI, Chen DC, Paz-Priel I. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.  Thromb Haemost. 2019 Jul;119(7):1084-1093.


Note: The session is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada.

To register for the LearnTransfusion series, send an email to learn.transfusion@blood.ca with  “Weekly Transfusion Medicine Seminars” in the subject line. Include your name and complete e-mail address in the body of the e-mail, and confirm that you would like to register for the LearnTransfusion series. You will then receive weekly email notifications of upcoming series events with details on how to join the webinars (e.g., call-in number and a link to register for the webinar).

The LearnTransfusion series is the seminar component of the Areas of Focused Competency (AFC)-Diploma Program in Transfusion Medicine. The series, organized by Canadian Blood Services is also open to all practitioners in the field of Transfusion Medicine. Through a series of regular webinars, trainees and practitioners are exposed to various scientific, technical and clinical aspects of transfusion medicine.